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A B S T R A C T
Management of lower urinary tract dysfunction (LUTD) in neurological diseases remains a priority
because it leads to many complications such as incontinence, renal failure and decreased quality of life. A
pharmacological approach remains the ﬁrst-line treatment for patients with neurogenic LUTD, but
electrical stimulation is a well-validated and recommended second-line treatment. However, clinicians
must be aware of the indications, advantages and side effects of the therapy. This report provides an
update on the 2 main electrical stimulation therapies for neurogenic LUTD – inducing direct bladder
contraction with the Brindley procedure and modulating LUT physiology (sacral neuromodulation, tibial
posterior nerve stimulation or pudendal nerve stimulation). We also describe the indications of these
therapies for neurogenic LUTD, following international guidelines, as illustrated by their efﬁcacy in
patients with neurologic disorders. Electrical stimulation could be proposed for neurogenic LUTD as
second-line treatment after failure of oral pharmacologic approaches. Nevertheless, further
investigations are needed for a better understanding of the mechanisms of action of these techniques
and to conﬁrm their efﬁcacy. Other electrical investigations, such as deep-brain stimulation and
repetitive transcranial magnetic stimulation, or improved sacral anterior root stimulation, which could
be associated with non-invasive and highly speciﬁc deafferentation of posterior roots, may open new
ﬁelds in the management of neurogenic LUTD.




Management of lower urinary tract dysfunction (LUTD) in
neurological diseases remains a priority. Indeed neurological
disorders such as multiple sclerosis and spinal cord injury (SCI) are
responsible for neurogenic detrusor overactivity (NDO) associated
with detrusor sphincter dyssynergia (DSD). DSD is characterized
by involuntary detrusor contractions during the bladder-ﬁlling
phase associated with lack of relaxation of the uretral-striated
sphincter, which leads to incontinence, urinary retention and
increased bladder pressure. The long-term result is upper urinary
tract deterioration. Urinary incontinence can negatively affect
quality of life (QoL). As well, patients with other neurological
diseases such as Parkinson’s disease (PD) and stroke [1,2] can
experience urinary urgency, incontinence or retention. The
prevalence of neurogenic LUTD depends on the type and duration
of neurological diseases and could affect from half to all patients* Corresponding author.
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.with neurological disorders [3] depending on the terminology used
to describe the LUT symptoms of interest [4].
The main goal of neurogenic LUTD management is regular,
complete bladder emptying, avoiding high intra-detrusor pressure,
and restoring continence so as to improve QoL and prevent
complications. Current NDO management relies on pharmaco-
therapy, acting primarily at the level of the efferent motor
micturition reﬂex branch, thereby allowing bladder ﬁlling at low
pressure. First-line treatment combines oral antimuscarinics with
or without intermittent bladder catheterization 5 to 6 times a day.
However, the efﬁcacy of antimuscarinics is limited, and atropinic
side effects decrease compliance.
Electrical stimulation (ES) was developed as second- or third-
line treatment for neurogenic LUTD and is now well validated and
accepted. Indeed, all scientiﬁc societies have reported the interest
of ES [5]. However, despite many recent reviews related to these
devices, several points need to be emphasized to provide the best
information for the best prescription.
This report provides an update on ES management of
neurogenic LUTD, focusing on the 2 main, although contrasting,
therapies (Table 1): stimulation to induce direct bladder
Table 1
Speciﬁcity of sacral anterior root stimulation and S3 neuromodulation.
Sacral anterior roots stimulation Neuromodulation
Population SCI (complete) MS/PD/Stroke
Indication NDO + DSD NDO
Principle Stimulation to induce detrusor contraction
for voiding and posterior rhizotomy to
achieve continence
Chronic stimulation to modulate
micturition reﬂex
Parameters of stimulation Several pulses of stimulation of
300 milliseconds with a frequency of
30 Hertz, only when micturition is desired
Permanent (Interstim) or prolonged stimulation with
waves of 200 ms and a frequency around 20 Hertz
Reversibility No Yes
Source of energy External controller and powered by radio
transmission
Intracorporeal batteries for interstim/extracorporeal
batteries for PTN/DGN
Site of stimulation Intradurally Extradurally S3/pudendal/posterior tibial nerve/dorsal genital nerve
SCI: spinal cord injury; MS: multiple sclerosis; PD: Parkinson disease; NDO: neurogenic detrusor activity; DSD: detrusor sphincter dyssynergia; PTN: posterior tibial nerve;
DGN: dorsal genital nerve.
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modulate LUT physiology. We emphasize the several indications
for the techniques in managing neurogenic LUTD, following
international guidelines, with evidence of their efﬁcacy in
patients with neurologic disorders.
2. Stimulation to induce direct detrusor contraction: sacral
anterior root stimulation (SARS) and posterior root rhizotomy
2.1. History
Since the discovery in the 18th century of the connection
between electricity and nerves, the collaboration between
engineers and physicians has led to numerous efﬁcient therapeu-
tics. In the urological ﬁeld, 2 major applications with two different
principles were developed: stimulation to induce a direct effect
and stimulation to modulate LUT physiology. For more than a
century, many sites have been stimulated, from the conus
medullaris to the pelvic ﬂoor and the detrusor. Researchers have
applied the technology in various pathologies, which has
progressively led to clear clinical indications. The major applica-
tions are the result of tremendous worldwide research efforts since
the 1950s.
Urinary retention due to detrusor areﬂexia was a real challenge
before the development of intermittent catheterization. In 1955,
MacGuire used various electrodes to stimulate the detrusor in dogs
[6]. Ten years later, Bradley et al. [7] developed an implantable
stimulator with 2 circular electrodes placed laterally to the
detrusor. However, only 2 of the 7 paraplegic patients could void
properly. Another approach was to use a metal electrode inserted
on an indwelling catheter.
Long-term chronic ES allows for achieving detrusor contraction.
This technique was developed by a Danish surgeon [8] to treat
chronic urinary retention after pelvic surgery. From these results,
Madersbasher et al. used the same type of chronic intravesical
stimulation in patients with myelomeningocele [9]. Direct ES of
the pelvic ﬂoor was also used to treat stress incontinence by
various teams, for example, Caldwell in 1963 [10]. Other sites were
tested with mixed results and major technical problems; one site
tested in 1971 was the spinal cord to stimulate the parasympa-
thetic center. The major advance was by Brindley, in 1977 [11],
who combined SARS and posterior radicotomy to treat urinary
incontinence and micturition disorders in patients with SCI.
2.2. Indication
SARS with posterior root rhizotomy can be proposed as a
validated option for managing NDO and dyssynergia in patientswith SCI because of research with long-term follow-up (grade B
evidence) [5–12]. Patients need to be properly assessed before
implantation because of the irreversibility of the approach. The
technique can be performed only in patients with SCI with
preserved sacral reﬂex and normal detrusor compliance. Because
all or a part of the posterior sacral nerves are destroyed, the
technique cannot be performed in patients with conserved lower
limb motility (grade B evidence) [5]. Moreover, this deafferenta-
tion induces sensory loss in the sacral dermatomes and patients
could lose reﬂexogenic erection. The principal indication is for
achieving urine continence and bladder voiding without catheter-
ization, even if this stimulation can also help with defecation and
erection.
2.3. Description of the technique
Brindley described SARS in the 1970s, with the ﬁrst human
implantations in 1972 [11]. The patient is under general anesthesia
to avoid drugs interfering with bladder contraction, which needs to
be recorded during surgery. Three approaches have been
described: intradural, extradural and sacral [13,14]. The technique
is separated into 3 parts. First, sacral roots are stimulated to
identify the motor (anterior) and sensory (posterior) roots and to
determine those involved in micturition by detrusor pressure
monitoring. Then 3 intracorporeal parts, including 4 slots with
3 platinum foil electrodes, 3 cables and a receiver block, are
implanted. The electrodes can be placed extradurally or intradu-
rally on the sacral roots from S2 to S4. Finally, the implantation is
accompanied by a larger posterior rhizotomy, to S4 [15]. This
rhizotomy, with its functional consequences, allows for complete
detrusor areﬂexia and normal bladder compliance (Fig. 1).
2.4. Mechanism of action
The purpose of the procedure is to allow for continence and
micturition. The micturition is obtained by several pulses of
stimulation of 300 ms at 30 Hz [16]. These intermittent stimula-
tions induce a prolonged contraction of the detrusor smooth
muscle while striated ﬁbres of the external urethral sphincter
undergo periods of relaxation during the ‘‘off’’ phase of intermit-
tent stimulation. This difference in relaxation and contraction time
between striated and smooth ﬁbres associated with posterior
rhizotomy prevents active dyssynergia. Patients often need several
courses of stimulation and subsequent ﬂow to empty the bladder
[12]. Dorsal root rhizotomy, extended to S4, interrupts afferent
synaptic transmission from the bladder, which is responsible for
the exacerbated micturition reﬂex with incontinence after SCI.
Because the efferent sacral somatic pathways are preserved, the
surgery induces no stress incontinence.
Fig. 1. Schematic representation of sacral anterior root stimulation and posterior root rhizotomy.
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SARS associated with posterior rhizotomy is an effective
technique after implantation. Indeed, the procedure can decrease
urinary-tract infection prevalence (68%), improve continence (54%)
and thus improve social life (54%) [17]. Moreover, a cystometric
study found signiﬁcant amelioration of elevated detrusor pressure,
low detrusor compliance and limited capacity in patients with SCI
[18]. An important advantage of the technique is restoration of
micturition without catheterization, with preservation of the upper
urinary tract [17]. Despite the efﬁcacy, the technique is not
commonly used because of the irreversibility and consequences
of the posterior rhizotomy as well as loss of reﬂex erection or vaginal
lubriﬁcation but also sensory loss in sacral dermatomes. Moreover,
accidental lesion of sacral motor roots could lead to permanent
incontinence and retention. Thus, only 2000 procedures have been
performed since the 1970s. A new approach of non-invasive and
highly speciﬁc deafferentation limited to bladder afferences would
provide continence and micturition without side effects, for a real
breakthrough in management of NDO.
3. Stimulation to modulate LUT physiology: S3
neuromodulation
3.1. History
Based on the results in cats published by Fall et al. [19], some
teams were involved in the development of ES in urology with the
principle of modulation. In fact, Fall et al. used cats to describe that
chronic ES of afferences in the pelvic nerve can modulate the
micturition reﬂex by different mechanisms: recruitment of
hypogastric activity or spinal interneurons. Different sites of
stimulation were used: pudendal nerve, posterior tibial nerve or
sacral root nerves (Fig. 2). Human proof-of-concept studies were
used to deﬁne the scientiﬁc background of the actual neuromo-
dulation techniques.3.2. Indication
This technique could be proposed for patients with neurological
disorders and NDO with failure of conventional pharmacotherapy
(grade D evidence). Indeed this technique is reversible and, despite
no well-established recommendations, can improve LUTD and QoL
(grade D evidence) [5]. However, as underlined by De Se`ze et al., S3
neuromodulation indications should be limited to patients without
urological risk factors and the follow-up should focus on risk
factors and adaptation of therapeutic modalities [20].
4. Sacral neuromodulation (SNM)
4.1. Description of the technique
SNM was ﬁrst described by Tanagho and Schmidt [21] for
treating non-neurogenic bladder dysfunction. The ﬁrst step
consists of implanting the electrode in the S3 root connected to
a temporary external stimulator, with an assessment, during at
least 1 week, of improvement in main symptoms. If the main
symptoms are improved enough (usually >50% improvement), a
second surgical procedure is performed to implant a permanent
intracorporeal stimulator connected to the S3 root electrode. This
approach in 2 steps allows for correct assessment with a low risk of
surgical complications and failure.
4.2. Mechanisms of action
The exact mechanism of action of neuromodulation in humans
is not clear. However, a few studies suggest an effect of SNM on
afferent sensory nerve ﬁbers, mainly corresponding to the S3 root,
which modulate voiding and continence reﬂex pathways in the
central nervous system [22,23]. Moreover C-ﬁbres may be
sensitized by infection, inﬂammation or neurogenic disorders
and convey erroneous excitatory inputs at the gate-control level of
the spinal cord. Thus, SNM could play a role in NDO by restoring the
Fig. 2. Schematic representation of S3 root neuromodulation.
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the bladder [24]. It could inhibit activation of the exacerbated
guard reﬂex after SCI and facilitate voiding by interrupting the
excitatory outﬂow of the external urethral sphincter [25]. Finally,
the role of cortico-subcortical structures was recently emphasized
in functional brain imaging studies [26].
4.3. Results and limitations of ES in neurogenic disorders
Kessler et al. described the efﬁcacy of SNM in patients 256 with
neurogenic LUTD [27]. An improvement of at least 50% in bladder
values recorded by diary (number of leakages, voids and cathete-
rizations as well as pad use) was considered a success. The pooled
success rate for permanent SNM was 92%, with a 99% probability that
the success rate was >75%. Overall, 69 patients reported an adverse
event, with 45 undergoing surgery because of an adverse event. The
most frequent adverse events were lead migration and pain at the
site of the permanent pulse generator. Furthermore, the device is
totally reversible and can allow for voiding without intermittent
catheterization. The clinical beneﬁts for patients with neurological
diseases seem to be interesting, with a low incidence of side effects,
which can be resolved with explantation.
Despite these results, SNM was not efﬁcient in patients with
complete chronic SCI [28], and further prospective trials with a
better assessment of neurological disorders including urodynamic
data are required to conﬁrm these results [29].
5. Percutaneous tibial nerve stimulation (PTNS)
5.1. Description of the technique
PTNS consists of stimulating the nerve by an electrode placed
5 cm above the medial malleolus. The correct positioning is
conﬁrmed by the ﬂexion of the big toe during stimulation.Intensity of the current is determined by the highest level the
patient can tolerate. The electric current is continuous, with a
square waveform, duration 200 ms and frequency 20 Hz. Usually,
patients perform one session of 30 min once a week for 12 weeks
[30].
5.2. Mechanisms of action
The posterior tibial nerve is derived from the L4-S3 nerve roots
and therefore shares common roots with those having bladder
functions. PTNS mechanisms of action still remain unclear. A few
papers suggest an effect on the detrusor with secondary decreased
neuronal metabolic activity of the sacral spinal cord innervating
the detrusor [31]. Others suggest a supraspinal effect, with a
signiﬁcant increase in amplitude of long latency somatosensory-
evoked potentials in humans [32].
5.3. Results and limitations in neurogenic disorders
Gaziev et al. described results of PTNS treatment in neurogenic
disease such as multiple sclerosis, SCI or Parkinson disease
[30]. Patients with Parkinson disease with detrusor overactivity
showed an increase in the ﬁrst involuntary detrusor contraction
volume and cystometric capacity during stimulation [33]. More-
over, a few studies have investigated the effect of PTNS in patients
with neurogenic LUTD related to multiple sclerosis. After 12 weeks
of treatment, urodynamic and clinical assessments showed
signiﬁcant improvement [34,35], although Fjorback et al. did not
obtain the same urodynamic results [36]. Only one long-term
study of PTNS for treating overactive bladder, not including
patients with neurologic diseases, showed a sustained improve-
ment for up to 12 months with periodic PTNS sessions [37]. De Se`ze
et al. concluded that chronic PTNS was effective for severe
overactive bladder in multiple sclerosis, without compromising
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improve symptoms even in the absence of an acute cystometric
effect. Although this treatment appears promising, further studies
conﬁrming its long-term efﬁciency are needed [38].
Thus, this technology can decrease NDO symptoms in patients
with neurologic disease, with any major adverse event described in
the literature. Only mild to moderate pain in the site of stimulation
was reported. Moreover, patients with neurologic disease showed
a signiﬁcant improvement in QoL [35]. Therefore, the technique
could be proposed for patients with neurogenic LUTD with lack of
efﬁcacy of pharmacologic therapies.
6. Pudendal and dorsal genital nerve neuromodulation
The pudendal and dorsal genital nerves are composed mainly of
afferent sensory ﬁbers from S2 (60%) and S3 (35%) but also S1 [32].
These roots are a major contributor to bladder afferent regulation
and function. Therefore, the mechanisms of action could be
compared to those of SNM. The dorsal genital nerve neuromodula-
tion involves transcutaneous stimulation [39], as compared with
pudendal neuromodulation, which requires electrode implantation
[40]. A few studies suggest improved continence associated with
increased detrusor capacity and decreased maximum detrusor
pressure [41,25]. The authors suggested that this technique could be
an effective alternative for neurogenic overactive bladder in patients
without response to antimuscarinic drugs and with poor results
from traditional sacral neuromodulation.
7. Other ES approaches to neurogenic LUTD
7.1. Intravesical ES
The ﬁrst intravesical ES (IVES) was described in 1878 by
Saxtorph [8] for treating atonic bladder with urinary retention by
transurethral bladder stimulation. The technique was reintrodu-
ced by Katona and Berenyi for neurogenic voiding disorders [42]. It
involves a catheter with a stimulation electrode introduced into
the bladder and connected to a stimulator. The anode is usually
attached to the skin in the lower arm or abdomen. The IVES effect
could result from direct activation of the Ad afferent ﬁbers with
low-threshold bladder mechanoreceptors, thus initiating and
maintaining the micturition reﬂex [43]. As well, IVES might
reduce C-ﬁber activity, thereby leading to NDO after SCI [44] and
inhibiting the spinal reﬂex pathway. Choi et al. analyzed IVES
therapy in children with spina biﬁda and NDO and DSD [45]. DSD
was resolved in about half after IVES. Incontinence with clean
intermittent catheterization was relieved: 47.9% of patients
showed reduced wetting between clean intermittent catheteriza-
tions. The authors reported an increase in detrusor contraction
ability in 48% of patients with an underactive bladder. Despite
these results, data are not sufﬁcient to support the development of
this approach for acontractile detrusor in this population because
the natural course of detrusor function in children with spina biﬁda
is not well known [46]. Nevertheless, international guidelines
recommend IVES as the only option to improve bladder sensation
and to enhance the micturition reﬂex in patients with incomplete
central or peripheral nerve damage, but controlled evidence is
needed (grade B evidence). Thus, the selection of patients is crucial
and IVES should be proposed for only neurogenic hyposensitive
and hypocontractile detrusors (grade C evidence) [5].
7.2. Brain stimulation
New approaches such as repetitive transcranial magnetic
stimulation (rTMS) or subthalamic nucleus [47] and thalamicdeep brain stimulation [48] may be promising for neurogenic
LUTD. Despite some promising results of rTMS in Parkinson disease
[49], multiple sclerosis [50] or incomplete SCI [51], further
investigations are needed to understand the mechanisms of these
techniques and demonstrate their efﬁcacy in neurogenic LUTD.
8. Conclusions
Because of the increase in evidence related to the efﬁciency of
ES devices and following international guidelines, ES could be
proposed for neurogenic LUTD as second-line treatment with
failure of pharmacologic approaches. Clinicians should be aware of
the indications, advantages and side effects of each technique.
However, individualised patient follow-up is required to safeguard
QoL and life expectancy, to prevent complications. Thus, all
patients with neurogenic LUTD, whatever the device used for
treatment, need to have a minimum follow-up, as described in
international guidelines [52]. Further investigations that may open
new ﬁelds in the management of neurogenic LUTD include deep
brain stimulation and rTMS or the improvement of SARS, which
could be associated with a non-invasive and highly speciﬁc
deafferentation of posterior roots.
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